Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. As per $HMTXF current market analysis...
Hemostemix is a biotechnology-based company located in Calgary, Canada, headed by Thomas A. Smeenk. The company deals with researching, developing, and manufacturing innovative blood-derived stem cells with miraculous healing and regeneration properties resulting in less immunogenic factors. It is a cost-effective platform that has the power to increase the...